AKT1 and non-small cell lung carcinoma: They demonstrated that the combination of an AKT inhibitor (MK2206), to suppress AKT phosphorylation or autophagy, with glucose deprivation and a GLUT1 specific inhibitor (STF-31) could tackle the resistance to erlotinib in NSCLC [347].